Headquartered in Mountain View, CA Fiscal year ends December NASDAQ: NPCE neuropace.com
NeuroPace, Inc. (Nasdaq: NPCE) is a medical device company focused on treating epilepsy. It develops and sells the RNS System, a brain-responsive neuromodulation platform. The device is implanted to detect abnormal brain activity and deliver personalized, real-time stimulation at the seizure source to reduce or eliminate seizures in patients with drug-resistant focal epilepsy.
The company earns nearly all of its revenue from RNS System sales to hospitals and epilepsy centers in the United States, plus a small amount of service revenue. It previously distributed DIXI Medical products, an operation now reported as discontinued.
NeuroPace is pursuing indication expansion and digital capabilities:
- A PMA supplement for idiopathic generalized epilepsy (IGE), with an amendment planned around year-end 2026.
- The AURORA real-world evidence study for adolescents aged 12–17.
- NeuroPace Remote Care, a telehealth programming capability submitted to the FDA.
- AI-powered software, including NeuroPace AI and ECoG Assistant.
- A next-generation device platform.
The company remains loss-making on a GAAP basis. It carries about $59.2 million of long-term debt and holds cash and short-term investments of roughly $49.5 million. Updated
NeuroPace cut full-year revenue guidance to $91 million to $92 million from $99.5 million to $101.5 million after a shortfall concentrated in a few of its largest accounts and a disruptive field sales reorganization. Management says fourth-quarter scheduled cases are already recovering, but the credibility damage lands first.
NeuroPace, Inc. (Nasdaq: NPCE) is a medical device company focused on treating epilepsy. It develops and sells the RNS System, a brain-responsive neuromodulation platform.
The Wall Street consensus 12-month price target for NPCE is $20.00.